

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A method to elicit a systemic, non-antigen-specific immune response in a mammal, comprising administering to said mammal a therapeutic composition by a route of administration selected from the group consisting of intravenous and intraperitoneal, said therapeutic composition comprising:

a. a cationic liposome delivery vehicle; and

b. ~~an isolated eukaryotic nucleic acid molecule without a gene insert, or a fragment thereof,~~

wherein said therapeutic composition elicits a systemic, non-antigen-specific immune response in said mammal and wherein said eukaryotic nucleic acid molecule comprises salmon sperm and/or calf thymus DNA does not comprise a bacterial nucleic acid sequence.

2. (Original) The method of claim 1, wherein said route of administration is intravenous.

3. (Canceled)

4. (Original) The method of claim 1, wherein said liposome delivery vehicle comprises lipids selected from the group consisting of multilamellar vesicle lipids and extruded lipids.

5. (Original) The method of claim 1, wherein said liposome delivery vehicle comprises multilamellar vesicle lipids.

6. (Canceled)

7. (Original) The method of claim 1, wherein said liposome delivery vehicle comprises pairs of lipids selected from the group consisting of DOTMA and cholesterol; DOTAP and cholesterol; DOTIM and cholesterol; and DDAB and cholesterol.

8. (Original) The method of claim 1, wherein said liposome delivery vehicle comprises DOTAP and cholesterol.

9. (Canceled)

10. (Original) The method of claim 1, wherein said composition has a nucleic acid to lipid ratio of about 1:1 to about 1:64.

11. (Original) The method of claim 1, wherein administration of said therapeutic composition elicits a systemic, anti-viral immune response in said mammal.

12. (Original) The method of claim 1, wherein administration of said therapeutic composition elicits a systemic, anti-tumor immune response in said mammal.

13. (Original) The method of claim 1, wherein administration of said therapeutic composition results in a reduction in a tumor in said mammal.

14. (Original) The method of claim 1, wherein administration of said therapeutic composition elicits a systemic, protective immune response against allergic inflammation in said mammal.

15. (Original) The method of claim 1, wherein administration of said therapeutic composition increases production of IFN γ in said mammal.

16. (Original) The method of claim 1, wherein administration of said therapeutic composition increases natural killer (NK) cell activity in said mammal.

17-18. (Canceled)

19. (Original) The method of claim 1, wherein said mammal is selected from the group consisting of humans, dogs, cats, mice, sheep, cattle, horses and pigs.

20. (Original) The method of claim 1, wherein said mammal is a human.

21-29. (Canceled)

30. (Currently amended) A method to elicit a systemic, non-antigen specific, immune response in a mammal that has cancer, wherein said immune response inhibits or reduces cancer growth in said mammal, said method comprising administering to said mammal a therapeutic composition by a route of administration selected from the group consisting of intravenous and intraperitoneal, said therapeutic composition comprising:

a. a cationic liposome delivery vehicle; and

b. ~~an isolated a eukaryotic nucleic acid molecule without a gene insert, or a fragment thereof;~~

wherein said therapeutic composition elicits a systemic, non-antigen-specific immune response in said mammal and wherein ~~said eukaryotic nucleic acid molecule comprises salmon sperm and/or calf thymus DNA does not comprise a bacterial nucleic acid sequence.~~

31-32. (Canceled)

33. (Currently amended) A method to elicit a systemic, non-antigen-specific, immune response in a mammal, wherein said immune response reduces allergic inflammation in said mammal, comprising administering to said mammal a therapeutic composition by a route of administration selected from the group consisting of intravenous and intraperitoneal, said therapeutic composition comprising:

a. a cationic liposome delivery vehicle; and

b. ~~an isolated a eukaryotic nucleic acid molecule without a gene insert, or a fragment thereof;~~

wherein said therapeutic composition elicits a systemic, non-antigen-specific immune response in said mammal and wherein said eukaryotic nucleic acid molecule comprises salmon sperm and/or calf thymus DNA ~~does not comprise a bacterial nucleic acid sequence~~.

34. (Canceled)